Document is current
Any future updates will be listed below
-
Authors
Arango, Celso https://orcid.org/0000-0003-3382-4754
Fegert, Joerg M. https://orcid.org/0000-0001-6070-4323
Picarel-Blanchot, Françoise https://orcid.org/0000-0001-8232-0793
Marx, Ute
Truffaut-Chalet, Lucie
Pénélaud, Pierre-François
Buitelaar, Jan https://orcid.org/0000-0001-8288-7757
,
-
Funding
Funding for this research was provided by:
Servier France
- License Information
-
More Information
Article History
Received: 16 June 2023
Accepted: 28 September 2024
First Online: 10 October 2024
Declarations
:
: Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Fegert has no potential conflicts with pharmaceutical companies to report during the past 3 years. Dr. Buitelaar has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Takeda, Roche, Medice, Angelini, Janssen, Boehringer-Ingelheim, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Françoise Picarel-Blanchot, Ute Marx, Lucie Truffaut-Chalet, and Pierre-François Penelaud are Servier employees.
: This study was performed in strict accordance with Good Clinical Practice. The patients (when intellectual maturity and capacity were appropriate) and their parents or their legally authorised representatives provided written informed consent prior to participation, in line with local regulatory requirements. The study was registered under EUDRACT No. 2015-002181-23.
